Prime Medicine, Inc. (PRME) Stock Analysis — Probabli.AI
AI-powered analysis for PRME (Prime Medicine, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. AI consensus: Bullish.
Last price: $3.43 · Market cap: $619.3M · AI consensus: Bullish
Prime Medicine, Inc. is positioned as an innovative leader in the gene editing and gene therapy field with high potential upside due to its groundbreaking technology and strong strategic initiatives. However, risks related to clinical results, regulatory hurdles, and market acceptance should not be overlooked. The positive analyst consensus coupled with recent funding rounds and partnerships…
Probabilistic 1-Year Outlook
- Bull 6000% · Neutral 3000% · Bear 1000%
- Prime Medicine's focus on breakthrough technology in gene editing and its ability to secure significant funding rounds position it for strong potential returns within the near term. Analyst targets suggest substantial…
5-Year Outlook
- Bull 7000% · Neutral 2000% · Bear 1000%
SWOT Highlights
- Strength: Innovative gene-editing technology
- Strength: Strong leadership and collaborations
- Risk: Currently unprofitable
- Risk: Dependent on successful clinical trials
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
6 Wall Street analysts rate PRME a BUY with a mean price target of $7.56.
Analysis generated Apr 11, 2026 · Model: gpt-4o. Run a fresh analysis on probabli.xyz/stock/PRME.
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.